title: [Results of combined therapy for 1260 patients with small cell lung cancer].
abstract: OBJECTIVE
  To evaluate the efficacy of combined modality treatment and determine the prognostic factors for small cell lung cancer (SCLC).
  
  
  METHODS
  From January 1974 to December 1995, 1260 patients with SCLC treated were retrospectively evaluated, with limited lesions in 732 patients, extensive lesions in 500 and stage unrecorded in 28. 553 patients were alloted into chemotherapy + radiotherapy (C + R) group, 355 into C + R + C group, 97 into R + C group, 126 into C group, 64 into R group and 65 into surgery (S + C + R) group. Patients with limited lesions received 2 - 4 cycles of chemotherapy including COMC, COMP, COMVP and CE-CAP. Radiotherapy was given to a dose of 40 - 70 Gy/4 - 7 w. Radiation portals for patients with limited lesions encompassed the primary tumor, hilar lymphatic drainage areas, partial mediastinum and bilateral supraclavicular regions. Patients with extensive lesions mainly received chemotherapy with or without palliative irradiation.
  
  
  RESULTS
  The overall CR and PR rates were 26.7% and 52.3%. Local recurrence and distant metastasis rates were 58.8% and 61.5%. The 1-, 3- and 5-year survival rates were 50.2%, 14.7% and 11.7%, with median survival time of 12 months. The era, sex, age, tumor stage and treatment modality were all significant prognostic factors by both uni-variate and multi-variate analyses (P < 0.05). The result of S + C + R rated the best among these modalities and the result of C + R + C was superior to C + R, though the difference of which was not significant.
  
  
  CONCLUSIONS
  Surgical resection should be considered as one part of comprehensive therapy for small cell lung cancer patients with limited lesions whenever possible. On top of routine chemotherapy early administration of radiotherapy is advisable.
authors.affiliation: Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
authors.forename: Dongfu
authors.initials: D
authors.lastname: Chen
authors.forename: Xiangru
authors.initials: X
authors.lastname: Zhang
authors.forename: Weibo
authors.initials: W
authors.lastname: Yin
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Miao
authors.forename: Fengyi
authors.initials: F
authors.lastname: Feng
authors.forename: Jinwan
authors.initials: J
authors.lastname: Wang
authors.forename: Mei
authors.initials: M
authors.lastname: Wang
authors.forename: Hongxing
authors.initials: H
authors.lastname: Zhang
authors.forename: Qinfu
authors.initials: Q
authors.lastname: Feng
authors.forename: Binghe
authors.initials: B
authors.lastname: Xu
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy; D015996:Survival Rate; D016896:Treatment Outcome